Aptevo to Participate in March Conferences
Aptevo Therapeutics (NASDAQ:APVO), a clinical-stage biotechnology company specializing in immuno-oncology therapeutics with proprietary ADAPTIR® and ADAPTIR-FLEX® platforms, has announced its participation in two major industry conferences this March.
The company will attend the 37th Annual Roth Conference from March 16-18, 2025, in Dana Point, CA, where they will engage in a fireside chat with analyst Jonathan Aschoff. The conference will feature one-on-one meetings, fireside chats, and industry panels, hosting executives from approximately 450 growth sector companies.
Additionally, Aptevo will participate in the Bio-Europe Springtime Partnering Event from March 17-19, 2025, in Milan, Italy. This event is expected to gather nearly 4,000 attendees, focusing on fostering relationships between biotechnology and biopharmaceutical companies.
Aptevo Therapeutics (NASDAQ:APVO), un'azienda biotecnologica in fase clinica specializzata in terapie immuno-oncologiche con piattaforme proprietarie ADAPTIR® e ADAPTIR-FLEX®, ha annunciato la sua partecipazione a due importanti conferenze del settore questo marzo.
L'azienda parteciperà alla 37ª Conferenza Annuale Roth dal 16 al 18 marzo 2025, a Dana Point, CA, dove parteciperà a una conversazione informale con l'analista Jonathan Aschoff. La conferenza presenterà incontri individuali, conversazioni informali e panel del settore, ospitando dirigenti di circa 450 aziende del settore in crescita.
Inoltre, Aptevo parteciperà all'Evento di Partnership Bio-Europe Springtime dal 17 al 19 marzo 2025, a Milano, Italia. Questo evento prevede la partecipazione di quasi 4.000 persone, con un focus sullo sviluppo di relazioni tra aziende biotecnologiche e biofarmaceutiche.
Aptevo Therapeutics (NASDAQ:APVO), una empresa de biotecnología en etapa clínica especializada en terapias de inmuno-oncología con plataformas propietarias ADAPTIR® y ADAPTIR-FLEX®, ha anunciado su participación en dos importantes conferencias de la industria este marzo.
La empresa asistirá a la 37ª Conferencia Anual Roth del 16 al 18 de marzo de 2025, en Dana Point, CA, donde participará en una charla informal con el analista Jonathan Aschoff. La conferencia contará con reuniones uno a uno, charlas informales y paneles de la industria, acogiendo a ejecutivos de aproximadamente 450 empresas del sector en crecimiento.
Además, Aptevo participará en el Evento de Asociaciones Bio-Europe Springtime del 17 al 19 de marzo de 2025, en Milán, Italia. Se espera que este evento reúna a casi 4,000 asistentes, centrado en fomentar relaciones entre empresas biotecnológicas y biofarmacéuticas.
Aptevo Therapeutics (NASDAQ:APVO)는 면역 종양학 치료제에 특화된 임상 단계의 생명공학 회사로, 독점적인 ADAPTIR® 및 ADAPTIR-FLEX® 플랫폼을 보유하고 있으며, 이번 3월에 두 개의 주요 산업 회의에 참여할 것이라고 발표했습니다.
회사는 2025년 3월 16일부터 18일까지 캘리포니아 다나 포인트에서 열리는 제37회 연례 로스 회의에 참석하여 분석가 조나단 애쇼프와의 대화에 참여할 예정입니다. 이 회의는 1:1 미팅, 대화 세션 및 산업 패널을 포함하며, 약 450개의 성장 산업 기업의 경영진이 참석할 것입니다.
또한 Aptevo는 2025년 3월 17일부터 19일까지 이탈리아 밀라노에서 열리는 Bio-Europe Springtime Partnering Event에 참여할 것입니다. 이 행사에는 거의 4,000명이 참석할 것으로 예상되며, 생명공학 및 생물 의약품 회사 간의 관계를 발전시키는 데 중점을 두고 있습니다.
Aptevo Therapeutics (NASDAQ:APVO), une entreprise de biotechnologie en phase clinique spécialisée dans les thérapies d'immuno-oncologie avec des plateformes propriétaires ADAPTIR® et ADAPTIR-FLEX®, a annoncé sa participation à deux grandes conférences du secteur ce mois de mars.
L'entreprise assistera à la 37ème Conférence Annuelle Roth du 16 au 18 mars 2025, à Dana Point, en Californie, où elle participera à une discussion informelle avec l'analyste Jonathan Aschoff. La conférence comprendra des réunions individuelles, des discussions informelles et des panels de l'industrie, accueillant des dirigeants d'environ 450 entreprises en croissance.
De plus, Aptevo participera à l'Événement de Partenariat Bio-Europe Printemps du 17 au 19 mars 2025, à Milan, en Italie. Cet événement devrait rassembler près de 4 000 participants, axé sur le développement de relations entre les entreprises biotechnologiques et biopharmaceutiques.
Aptevo Therapeutics (NASDAQ:APVO), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Immunonkologie-Therapeutika mit den proprietären Plattformen ADAPTIR® und ADAPTIR-FLEX® spezialisiert hat, hat seine Teilnahme an zwei wichtigen Branchenkonferenzen im März bekannt gegeben.
Das Unternehmen wird an der 37. jährlichen Roth-Konferenz vom 16. bis 18. März 2025 in Dana Point, Kalifornien, teilnehmen, wo es ein informelles Gespräch mit dem Analysten Jonathan Aschoff führen wird. Die Konferenz umfasst Einzelgespräche, informelle Gespräche und Branchenpanels und wird Führungskräfte von etwa 450 Wachstumsunternehmen beherbergen.
Zusätzlich wird Aptevo am Bio-Europe Springtime Partnering Event vom 17. bis 19. März 2025 in Mailand, Italien, teilnehmen. Es wird erwartet, dass diese Veranstaltung nahezu 4.000 Teilnehmer anzieht und sich auf den Aufbau von Beziehungen zwischen biotechnologischen und biopharmazeutischen Unternehmen konzentriert.
- None.
- None.
SEATTLE, WA / ACCESS Newswire / March 6, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today announced that the Company is participating in two conferences in March, as follows:
The 37th Annual Roth Conference March 16-18, 2025 in Dana Point, CA. Aptevo will participate in a fireside chat with covering analyst Jonathan Aschoff while onsite.
The conference will consist of 1-on-1 / small group meetings, analyst-selected fireside chats, industry keynotes and panels with executive management attending from approximately 450 private and public companies in a variety of growth sectors
Bio-Europe Springtime Partnering Event March 17-19, 2025 in Milan, Italy.
The event brings together almost 4,000 attendees, facilitates relationship building and meetings between and among companies across the biotechnology and biopharmaceutical industries.
About Aptevo Therapeutics
Aptevo Therapeutics Inc. (NASDAQ:APVO) is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The company has two clinical candidates. Mipletamig is currently being evaluated in RAINIER, a Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation ("orphan status") for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates were created from two proprietary platforms, ADAPTIR® and ADAPTIR-FLEX® The Aptevo mission is to improve treatment outcomes and transform the lives of cancer patients. For more information, please visit www.aptevotherapeutics.com.
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, Aptevo's expectations about the activity, efficacy and safety of its therapeutic candidates and potential use of any such candidates as therapeutics for treatment of disease, its expectations regarding the effectiveness of its ADAPTIR and ADAPTIR-FLEX platforms, statements related to the progress of Aptevo's clinical programs and any other statements containing the words "may," "continue to," "believes," "expects," "optimism," "potential," "designed," "promising," "plans," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Aptevo's current intentions, beliefs, and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo's expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement.
There are several important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo's business or prospects; further assessment of preliminary data or different results from later clinical trials; adverse events and unanticipated problems, adverse developments in clinical development, including unexpected safety issues observed during a clinical trial; and changes in regulatory, social, macroeconomic and political conditions. For instance, actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the uncertainties inherent in the results of preliminary data and preclinical studies being predictive of the results of later-stage clinical trials, initiation, enrollment and maintenance of patients, and the completion of clinical trials, the availability and timing of data from ongoing clinical trials, the trial design includes combination therapies that may make it difficult to accurately ascertain the benefits of mipletamig, expectations for the timing and steps required in the regulatory review process, expectations for regulatory approvals, the impact of competitive products, our ability to enter into agreements with strategic partners or raise funds on acceptable terms or at all and other matters that could affect the availability or commercial potential of Aptevo's product candidates, business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises such as the coronavirus (referred to as COVID-19), geopolitical risks, including the current war between Russia and Ukraine and the war between Hamas and Israel, and macroeconomic conditions such as economic uncertainty, rising inflation and interest rates, increased market volatility and decreased consumer confidence. These risks are not exhaustive, Aptevo faces known and unknown risks. Additional risks and factors that may affect results are set forth in Aptevo's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and its subsequent reports on Form 10-Q and current reports on Form 8-K. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Aptevo's expectations in any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not assume any obligation to update any forward-looking statement to reflect new information, events, or circumstances.
Contact Information
Miriam Miller
Head, IR and Corporate Communications
millerm@apvo.com
206-859-6628
SOURCE: Aptevo Therapeutics
View the original press release on ACCESS Newswire
FAQ
What conferences will Aptevo Therapeutics (APVO) attend in March 2025?
What is the focus of Aptevo's (APVO) therapeutic development platform?
How many companies will participate in the 2025 Roth Conference where APVO is presenting?
What activities will APVO participate in at the 2025 Roth Conference?
How many attendees are expected at the 2025 Bio-Europe event where APVO will participate?
